Onkologie 2020: 14(Suppl.A): 5-8 | DOI: 10.36290/xon.2020.027

Incidental finding of pancreatic duct dilation as the sign of asymptomatic pancreatic cancer

Pavel Záruba, Miroslav Ryska
Chirurgická klinika 2. LF UK a ÚVN
Ústřední vojenská nemocnice - Vojenská fakultní nemocnice, Praha

Pancreatic carcinoma has a poor prognosis. Typically, it hasn´t any specific symptoms in the early stages. Incidentally found dilation of pancreatic duct could be this sign. When it´s present there active approach and correct evaluation of all results are needed. The case study presents patient in oncological follow-up diagnosed for pancreatic duct dilation without any clinical signs. The initial imaging examination didn´t explain any cause of dilation. After that, the patient was diagnosed and operated for the malignant lesion of the pancreatic head.

Keywords: pancreatic cancer, pancreatic duct dilation, second primary tumor.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Záruba P, Ryska M. Incidental finding of pancreatic duct dilation as the sign of asymptomatic pancreatic cancer. Onkologie. 2020;14(Suppl.A / Onkologické kazuistiky 1):5-8. doi: 10.36290/xon.2020.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Novotvary 2016 (online). Národní onkologický registr. ÚZIS. Dostupné z: http://www.uzis.cz/katalog/zdravotnicka-statistika/novotvary.
    2. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1): 10-27. Go to original source...
    3. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11): 1039-1049. Go to original source...
    4. Záruba P, Ryska M. Surgical treatment of pancreatic carcinoma. Rozhl Chir. 2019; 91(12): 702-709.
    5. Edge MD, Hoteit M, Patel AP, Wang X, Baumgarten DA, Cai Q. Clinical significance of main pancreatic duct dilation on computed tomography: single and double duct dilation. World J Gastroenterol. 2007; 13(11): 1701-1705. Go to original source...
    6. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008; 191(3): 802-807. Go to original source... Go to PubMed...
    7. Koubková L, Hrstka R, Dobes P, Vojtesek B, Vyzula R. Second primary cancers - causes, incidence and the future. Klin Onkol. 2014; 27(1): 11-7. Go to original source... Go to PubMed...
    8. Baxi AC, Jiang Q, Hao J, Yang Z, Woods K, Keilin S, Willingham FF, Cai Q. The effect of solid pancreatic mass lesions on pancreatic duct diameter at endoscopic ultrasound. Endosc Ultrasound. 2017; 6(2): 103-108. Go to original source... Go to PubMed...
    9. Deerenberg EB, Poley JW, Hermans JJ, Ganesh S, van der Harst E, van Eijck CH. Role of endoscopic ultrasonography in patients suspected of pancreatic cancer with negative helical MDCT scan. Dig Surg. 2011; 28(5-6): 398-403. Go to original source... Go to PubMed...
    10. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2015 Pancreatic Adenocarcinoma. http://www.nccn.org
    11. Vasen HFA, Boekestijn B, Ibrahim IS, Inderson A, Bonsing BA, de Vos Tot Nederveen Cappel WH, Feshtali S, Wasser MN. Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program. HPB (Oxford). 2019 Mar 22. Go to original source...
    12. Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014 Aug; 35(8): 7459-7465. Go to original source...
    13. Yamaguchi K, Okusaka T, Shimizu K, Furuse J, Ito Y, Hanada K, Shimosegawa T,Okazaki K; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis. Pancreas. 2017; 46(5): 595-604. Go to original source... Go to PubMed...
    14. Wang W, Shpaner A, Krishna SG, Ross WA, Bhutani MS, Tamm EP, Raju GS, Xiao L, Wolff RA, Fleming JB, Lee JH. Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT. Gastrointest Endosc. 2013; 78(1): 73-80. Go to original source...
    15. Bipat S, Phoa SS, van Delden OM et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005; 29: 438-445. Go to original source...
    16. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, Macari M,Megibow AJ, Miller FH, Mortele KJ, Merchant NB, Minter RM, Tamm EP, Sahani DV,Simeone DM. Pancreatic ductal adenocarcinoma radiology reporting template:consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014; 146(1): 291-304. Go to original source...
    17. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012; 36(4): 884-891. Go to original source... Go to PubMed...
    18. Bell R, Ao BT, Ironside N, Bartlett A, Windsor JA, Pandanaboyana S. Meta-analysis and cost effective analysis of portal-superior mesenteric vein resection during pancreatoduodenectomy: Impact on margin status and survival. Surg Oncol. 2017; 26(1): 53-62. Go to original source...
    19. Ragulin-Coyne E, Carroll JE, Smith JK, et al. Perioperative mortality after pancreatectomy: a risk score to aid decision-making. Surgery 2012; 152(3 Suppl.1): S120-S127. Go to original source... Go to PubMed...
    20. Nikov A, Záruba P, Bělina F, Ryska M. Pankreatoduodenektomie pro karcinom pankreatu u seniorů - zkušenosti jednoho centra. Rozhl Chir, 2018; 97(1): 34-38.
    21. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012; 18(16): 4266-4276. doi: 10.1158/1078-0432.CCR-11-3114. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.